Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM

NCT06660173 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06660173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 7, 2024
Completion date
November 10, 2026
Enrollment
409 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus (t2dm)